Bevacizumab exerts anti-angiogenic effects in cancer patients by inhibiting vascular endothelial growth factor (VEGF). However, its use is still limited due to the development of resistance to the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback